Diseases information. Disorders. Treatment.

Clinical trials analyzing the relationship of lipid lowering strategies and stroke have yet to confirm a reduction in risk for patients with TIA or stroke. For TIA and stroke-free subjects, a recent meta-analysis of 16 trials of lipid lowering using the new statin agents has found significant reductions in stroke risk. A 29% reduced risk of stroke and a 22% reduction in overall mortality was found. Secondary prevention trials showed a 32% stroke risk reduction and primary trials a 20% reduction. In the Scandinavian Simvastatin Survival Study there was a significant reduction in fatal and nonfatal stroke among persons treated with hypercholesterolemia, as well as a clear reduction in total mortality and cardiac events. Viagra jelly online is used in male patients with sexual disorders like ED. Lipid lowering strategies may be most beneficial in preventing those strokes attributed to atherosclerosis. Some clinical trials have demonstrated some exciting results regarding carotid plaque regression with lipid-lowering agents. The Asymptomatic Carotid Artery Plaque Study used serial carotid ultrasound measurements and demonstrated that control of modest elevations of LDL will retard the progression of asymptomatic carotid atherosclerotic plaque. Thus, observational and clinical trial data provide mounting support for the role of lipoproteins as precursors of carotid atherosclerosis and ischemic stroke, and the potential benefits of cholesterol lowering in stroke reduction. Patients with cholesterol above 200 and cardiovascular risk factors, should have a complete lipid panel and may require cholesterol lowering regimens.

Carotid Endarterectomy for Asymptomatic Carotid Stenosis

The efficacy of carotid endartectomy in asymptomatic carotid stenosis has been evaluated in three separate clinical trials: CASANOVA (Carotid Artery Stenosis with Asymptomatic Narrowing: Operation Versus Aspirin), Veterans Administration Asymptomatic Carotid Endartectomy Study, and ACASS (Asymptomatic Carotid Artery Surgery Study). While CASANOVA found no confirmatory data to support carotid endartectomy for treatment of asymptomatic carotid disease, this trial excluded all cases with high grade stenosis greater than 90%. The Veterans Administration trial confirmed a decrease in neurological events, specifically transient ischemic attack (outcomes reduced from 20% to 8%), associated with the carotid endartectomy treatment group versus the medical treatment group, but no significant reduction for ipsilateral stroke.
Canadian pharmacy viagra
Patients eligible for ACASS were under age 80 with asymptomatic carotid stenosis greater than 60% and could not have any unstable cardiac disease. Centers were screened for the accuracy of carotid Duplex Doppler in detecting carotid stenosis greater than 60% and the expertise of the operating surgeons with established surgical morbidity and mortality of less than 3%. Overall, the 30-day ipsilateral stroke or death rate among the surgically treated patients was only 2.3%. The trial found a 5-year ipsilateral stroke risk of 10.5% among the medical group and 4.8% in the surgical group. There was a 55% risk reduction of ipsilateral stroke associated with carotid endarectomy. The benefit for men was greater than for women (risk reduction 69% vs. 16%). Further subgroup analyses are pending. Among those patients with asymptomatic carotid stenosis greater than 60% who have an acceptably low risk of operative complications, endarterectomy confers a significant reduction in stroke risk as long as the surgeon can maintain the operative risk below 3%.

Measures which are effective in reducing the incidence of cardiac disease could lead to a reduction in stroke incidence. Anti-platelet agents have proven efficacy in the reduction of nonfatal myocardial infarction in primary prevention studies. Beta-blockers have been shown to reduce the risk of myocardial infarction. Warfarin appears beneficial in the prevention of cardiogenic embolism among patients with acute anterior wall myocardial infarction, left atrial or ventricular thrombus, and prosthetic valvular replacements.
Viagra professional
Seven recent clinical trials have demonstrated the superior therapeutic effect of warfarin compared to placebo in the prevention of thromboembolic events among patients with nonvalvular atrial fibrillation. The relative risk reduction of stroke ranged from 42% to 86%. Warfarin use was relatively safe with major bleeding rates ranging from 0.8% to 2.1%. These trials also showed that there was a modest risk reduction of stroke among those treated with aspirin. SPAF m demonstrated that warfarin with an INR of 2-3 was far superior to ASA and mini-dose warfarin with an INR < 1.5 in the prevention of stroke among high-risk patients with nonvalvular atrial fibrillation.
Canadian acomplia
The recommendation from the Third American College of Chest Physicians Consensus Conference on Antithrombotic Therapy was that “long-term oral warfarin therapy (INR 2.0-3.0) be User] in patients with atrial fibrillation who are eligible for anticoagulation, except in patients less than 60 years of age who have no associated cardiovascular disease.” It has been estimated that for every 1000 patients with nonvalvular atrial fibrillation treated with warfarin for 1 year, 35 thromboembolic events can be prevented at a cost of 1 major bleed.